Cargando…

Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.

The expression of pS2 was examined histochemically in paraffin sections taken from biopsy material from patients diagnosed with ductal carcinoma in situ (DCIS). Often intense immunoreactivity, to an anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of D...

Descripción completa

Detalles Bibliográficos
Autores principales: Luqmani, Y. A., Campbell, T., Soomro, S., Shousha, S., Rio, M. C., Coombes, R. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968340/
https://www.ncbi.nlm.nih.gov/pubmed/8385977
_version_ 1782134718900207616
author Luqmani, Y. A.
Campbell, T.
Soomro, S.
Shousha, S.
Rio, M. C.
Coombes, R. C.
author_facet Luqmani, Y. A.
Campbell, T.
Soomro, S.
Shousha, S.
Rio, M. C.
Coombes, R. C.
author_sort Luqmani, Y. A.
collection PubMed
description The expression of pS2 was examined histochemically in paraffin sections taken from biopsy material from patients diagnosed with ductal carcinoma in situ (DCIS). Often intense immunoreactivity, to an anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of DCIS, with significant positivity found in 63-67% of cases. In 15 samples analysed, we found a good correlation between pS2 expression and presence of progesterone receptor positive cells, but not with estrogen receptor. There was only a limited degree of correspondence between the cells staining with these anti-sera. Some pS2 positive cells were also seen in normal acini in areas adjacent to cancer but much less frequently in sections of normal breast from reduction mammoplasty. Most normal areas were negative, as were cysts. In benign proliferative conditions (seen in sections with and without DCIS) such as adenosis, sclerosing adenosis, mild and florid ductal epithelial hyperplasia, significant pS2 positivity was seen in about 50% of cases. These results suggest that there is a progressive increase in pS2 from normal to benign to cancer cells and that this gene is expressed in both the invasive and pre-invasive forms of breast cancer. IMAGES:
format Text
id pubmed-1968340
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19683402009-09-10 Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Luqmani, Y. A. Campbell, T. Soomro, S. Shousha, S. Rio, M. C. Coombes, R. C. Br J Cancer Research Article The expression of pS2 was examined histochemically in paraffin sections taken from biopsy material from patients diagnosed with ductal carcinoma in situ (DCIS). Often intense immunoreactivity, to an anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of DCIS, with significant positivity found in 63-67% of cases. In 15 samples analysed, we found a good correlation between pS2 expression and presence of progesterone receptor positive cells, but not with estrogen receptor. There was only a limited degree of correspondence between the cells staining with these anti-sera. Some pS2 positive cells were also seen in normal acini in areas adjacent to cancer but much less frequently in sections of normal breast from reduction mammoplasty. Most normal areas were negative, as were cysts. In benign proliferative conditions (seen in sections with and without DCIS) such as adenosis, sclerosing adenosis, mild and florid ductal epithelial hyperplasia, significant pS2 positivity was seen in about 50% of cases. These results suggest that there is a progressive increase in pS2 from normal to benign to cancer cells and that this gene is expressed in both the invasive and pre-invasive forms of breast cancer. IMAGES: Nature Publishing Group 1993-04 /pmc/articles/PMC1968340/ /pubmed/8385977 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Luqmani, Y. A.
Campbell, T.
Soomro, S.
Shousha, S.
Rio, M. C.
Coombes, R. C.
Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
title Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
title_full Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
title_fullStr Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
title_full_unstemmed Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
title_short Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
title_sort immunohistochemical localisation of ps2 protein in ductal carcinoma in situ and benign lesions of the breast.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968340/
https://www.ncbi.nlm.nih.gov/pubmed/8385977
work_keys_str_mv AT luqmaniya immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast
AT campbellt immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast
AT soomros immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast
AT shoushas immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast
AT riomc immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast
AT coombesrc immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast